LEGN
Legend Biotech Corp
$27.08
-0.30 (-1.10%)
At close · Jul 10
Market Cap
$5.24B
Shares
193,439,792
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.08
Open$27.45
Day$26.52–27.53
52W$16.24–45.30
Avg vol 30d2.9M
Short int13.1M · 6.8% float · 4.2d
Short vol46%
Last earningsMar 31, 2026
DataJun 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
−8%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
37%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
+22%
trailing
YTD return
+25%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
8 of 192 funds reported for Jun 30 · net +1.9M sh shares · +4 new
Insider flow
Distributing
Net -$171.1K over 90 days · 100% sells
Short interest
Rising
6.78% of float · ▲ +1.0% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
192 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Gross margin on net product sales
· second quarter
at least 50%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
37%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
8 of 192 funds reported for Jun 30 · net +1.9M sh shares · +4 new
Insider flow
Distributing
Net -$171.1K over 90 days · 100% sells
Short interest
Rising
6.78% of float · ▲ +1.0% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
192 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $16
Now $27 · 37%
52-wk high $45
vs 200-day avg +7%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss non-GAAP | $11M | Q1 2026 call | — |
| CARVYKTI global markets | 18 | Q1 2026 call | — |
| CARVYKTI manufacturing success rate | 99% | Q1 2026 call | — |
| CARVYKTI median turnaround time | 29 | Q1 2026 call | — |
| CARVYKTI net trade sales | $597M | Q1 2026 call | — |
| CARVYKTI net trade sales sequential growth | 8% | Q1 2026 call | — |
| CARVYKTI second and third line share of U.S. apheresis volume | 41% | Q1 2026 call | — |
| CARVYKTI second and third line share of U.S. apheresis volume prior year | 29% | Q1 2025 call | — |
| CARVYKTI U.S. year-over-year growth | 36% | Q1 2026 call | — |
| Gross margin on net product sales | 41% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEGN
this stock
Legend Biotech Corp
|
$5.24B | +24.6% | — | — | 6.8% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.76B | +4.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEGN | -9.5% | -22.3% | +22.5% | -6.2% | +24.6% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -10.8% | -26.4% | +13.4% | -7.3% | +13.9% |
Key facts
CIK
1801198
CUSIP
52490G102
13F (30d)
19 filings
9 filers
Visit website
Investor relations